Hutchison MediPharma Founder And CEO Samantha Du On China's Drug R&D Ecosystem: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
Among the first wave of returnees back to China, Samantha Du, who conducted global licensing for metabolic diseases with Pfizer, and cofounded Hutchison Chi-Med., returned to Shanghai to start biotech company Hutchison MediPharma in 2002
You may also be interested in...
Asia Spotlight: Meet China’s New Innovators – Hua Medicine Looks To Take Flight With U.S. Venture Backing
On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.
Asia Spotlight: Meet China’s New Innovators – Hua Medicine Looks To Take Flight With U.S. Venture Backing
On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.
Creative Funding Options For China; Investors Battle Perception of Home Court Advantage
The growth in available government funding for pharmaceutical companies in China is creating a snowball of investment from domestic and multinational pharma companies more willing to overcome intellectual property concerns